|
1 Indications And Usage Bynfezia Pen Is A Somatostatin Analogue Indicated For: Reduction Of Growth Hormone (Gh) And Insulin-Like Growth Factor 1 (Igf-1) [Somatomedin C] In Adult Patients With Acromegaly Who Have Had Inadequate Response To Or Cannot Be Treated With Surgical Resection, Pituitary Irradiation, And Bromocriptine Mesylate At Maximally Tolerated Doses (1.1) Treatment Of Severe Diarrhea/flushing Episodes Associated With Metastatic Carcinoid Tumors In Adult Patients (1.2) Treatment Of Profuse Watery Diarrhea Associated With Vasoactive Intestinal Peptide Tumors (Vipomas) In Adult Patients (1.3) Limitations Of Use: In Patients With Acromegaly, The Effect Of Bynfezia Pen On Improvement In Clinical Signs And Symptoms, Reduction In Tumor Size And Rate Of Growth, Has Not Been Determined. (1.4) In Patients With Carcinoid Syndrome And Vipomas, The Effect Of Bynfezia Pen On Size, Rate Of Growth And Development Of Metastases, Has Not Been Determined. (1.4) 1.1 Acromegaly Bynfezia Pen Is Indicated To Reduce Blood Levels Of Growth Hormone (Gh) And Insulin-Like Growth Factor 1 (Igf-1) [Somatomedin C] In Adult Patients With Acromegaly Who Have Had Inadequate Response To Or Cannot Be Treated With Surgical Resection, Pituitary Irradiation, And Bromocriptine Mesylate At Maximally Tolerated Doses. 1.2 Carcinoid Tumors Bynfezia Pen Is Indicated For The Treatment Of Adult Patients With Severe Diarrhea And Flushing Episodes Associated With Metastatic Carcinoid Tumors. 1.3 Vasoactive Intestinal Peptide Tumors (Vipomas) Bynfezia Pen Is Indicated For The Treatment Of Adult Patients With The Profuse Watery Diarrhea Associated With Vip-Secreting Tumors. 1.4 Limitations Of Use In Patients With Acromegaly, The Effect Of Bynfezia Pen On Improvement In Clinical Signs And Symptoms, Reduction In Tumor Size, And Rate Of Growth Has Not Been Determined. In Patients With Carcinoid Syndrome And Vipomas, The Effect Of Bynfezia Pen On The Tumor Size, Rate Of Growth And Development Of Metastases Has Not Been Determined.
|